捐血输血诊断市场报告：2031 年趋势、预测与竞争分析

全球捐赠者输血诊断市场前景光明，血库和捐血市场蕴藏着巨大机会。预计2025年至2031年期间，全球捐赠者输血诊断市场的复合年增长率将达到6.9%。推动该市场发展的关键因素包括：对安全输血和预防输血相关感染的先进诊断检测的需求不断增长；血液疾病和需要输血的外科手术的患病率不断上升；血液检测技术的进步；以及血液安全监管标准的不断提高。

Lucintel 预测，由于诊断套件和套件的成本效益和在各种医疗保健环境中的易用性，它们将在预测期内实现高速成长。

根据应用，由于严格的监管要求和大量的血液收集和储存，血库预计将实现高速成长。

根据地区划分，由于严格的法律规范和对医疗保健系统的大量投资，预计北美将在预测期内实现最高成长。

我们超过 150 页的综合报告提供宝贵见解，协助您的业务决策。以下是一些范例资料和见解：

捐赠者输血诊断市场的新趋势

新兴趋势正以闪电般的速度改变捐血者输血诊断市场的模式。技术进步、监管变化和市场需求正在推动这些变化。重点在于提高诊断准确性，降低输血不良併发症的风险，并优化捐血管理流程。以下是当今市场的五大关键趋势：

• 人工智慧与血液筛检的整合：在捐血者筛检测试中引入基于人工智慧的解决方案旨在提高诊断的准确性和效率。人工智慧演算法不断学习和分析捐血者血液的复杂模式，这有助于识别病原体、实现血液相容性并找到最佳输血配型。由于能够快速获得结果，并最大限度地减少人为失误，输血变得更加安全。随着人工智慧的进步，这项技术可能会彻底改变捐血者输血的整个诊断流程，从而实现更快、更可靠的筛检。
• 核酸检测的进展：核酸检测 (NAT) 已成为识别捐赠血液中病原体的重要工具。 NAT 方法能够高灵敏度地检测出爱滋病毒和肝炎等病毒感染，从而提高输血用血液製品的安全性。在大多数地区，NAT 现已成为常规检测程序的一部分，有助于提高捐血的品质并降低输血传播感染的风险。 NAT 的推广应用对全球迈向更安全的输血运动做出了重大贡献。
• 转型为自动化血液筛检系统：自动化正在改变血液筛检的方式。目前，许多高容量检测都是透过利用血液检测自动化系统以高精度完成的。自动化使检测速度更快、更准确，因为检测更容易完成，从而降低了人工成本并最大限度地减少了人为错误。就筛检而言，自动化操作还提高了可扩展性，这意味着更容易增加血液检测量，并且可以在高度安全的条件下进行更多捐血。
• 聚焦病原体灭活技术：病原体灭活技术在安全输血的应用日益广泛。这些方法旨在消除捐血中任何病原体的存在，同时又不损害捐血的品质。新型感染疾病和多重抗药性细菌的出现推动了对先进灭活方法的需求。病原体灭活技术正成为捐血诊断和处理工作流程中不可或缺的一部分。
• 监管变化和更高标准：世界各地的监管机构正在更新和加强对捐血和输血诊断的要求。用于更严格筛检和诊断流程的新技术正在纳入捐血流程。监管变化迫使市场创新，提供更安全、更高品质的血液製品。监管变化也为企业创造了开发创新诊断工具的机会，有助于提供更安全的捐血。

捐赠者输血诊断市场的新趋势，包括人工智慧的整合、核酸检测的进步、自动化和病原体灭活技术，正在提高血液筛检的效率、准确性和安全性。这些技术创新显着改善了诊断流程，降低了输血相关风险，并简化了血液管理。随着这些趋势的不断发展，它们将重塑市场，并有助于提高全球输血业务的安全性和业务效率。

捐赠者输血诊断市场的最新趋势

捐献输血诊断市场的最新进展凸显了目前对提高血液安全、诊断和业务效率的日益重视。越来越多的技术和研究投入用于简化诊断流程、提高病原体检测能力，同时确保更高品质的血液製品。目前推动市场发展的五大进展是：

• 基于人工智慧的血液筛检：人工智慧已成为血液筛检方法进步不可或缺的一部分。人工智慧演算法如今正帮助识别捐血中潜在的不相容性、异常情况和病原体。与传统的人工方法相比，这确保了更高的准确性和更快的结果。随着人工智慧的不断发展，它在改善捐血者筛检和输血安全方面拥有更大的潜力，使其成为未来血液检测创新的基石。
• 核酸检测 (NAT) 的进展：随着新技术的出现，核酸检测 (NAT) 已显着改进，能够更快、更准确地检测出捐血中的病毒病原体。 NAT 在常规筛检中的广泛应用显着降低了输血传染感染的风险，从而提高了全球输血的整体安全性。 NAT 技术的持续改进预计将进一步提高这些诊断工具的检测能力。
• 自动筛检系统引入：自动血液筛检系统的日益普及，透过提高通量并最大限度地减少人为错误，正在颠覆市场。这些系统缩短了处理时间，并能够有效地检测大量捐血。自动化检测流程有助于降低营运成本，最大限度地降低与手动任务相关的风险，并提高血液筛检程序的整体可靠性。
• 用于病原体检测的新一代定序 (NGS)：第三代定序仪将NGS技术引入血液检测，并实现了血液的高级筛检，实现了超灵敏且高选择性的病原体检测。例如，稀有病原体、新近出现的病原体以及广泛传播的感染疾病已被识别，准确率高于其他病原体。这可用于检查捐血的安全性，因为先前未知的疾病正迅速成为威胁。
• 更优血液检测套件：新型血液检测试剂套件已面世，旨在提高血液检测的准确性、速度和成本。这些套件可用于偏远地区和医院，可望提升低度开发国家输血的安全性。

捐赠者输血诊断市场的最新进展是基于人工智慧筛检、先进的病原体检测、自动化技术以及改进的诊断试剂套件，从而提高了血液安全性和检测准确性。这些创新也降低了营运成本和侦测时间，推动市场迈向更有效率、更具可扩展性的解决方案迈进。随着这些技术被整合到全球输血系统中，它们将继续改善捐血的整体安全性和管理。

目录

第一章执行摘要

2. 全球捐血输血诊断市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章 2019年至2031年市场趋势及预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球捐赠者输血诊断市场趋势（2019-2024）及预测（2025-2031）
• 按类型
  • 装置
  • 套件和试剂
• 按用途
  • 血库
  • 捐血
  • 其他的

第四章2019年至2031年区域市场趋势与预测分析

• 按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按类型
  • 按用途
  • 按地区
• 全球捐赠输血诊断市场的新趋势
• 战略分析
  • 新产品开发
  • 全球捐献输血诊断市场容量不断扩大
  • 全球捐赠者输血诊断市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业简介

• Grifols
• F. Hoffmann-La Roche
• Abbott
• Bio-Rad Laboratories
• Werfen
• Quidelortho Corporation
• Alivedx Holdings Finance
• Bag Diagnostics Gmbh
• Diasorin
• Prestige Diagnostics

The future of the global donor transfusion diagnosis market looks promising with opportunities in the blood bank, blood donation markets. The global donor transfusion diagnosis market is expected to grow with a CAGR of 6.9% from 2025 to 2031. The major drivers for this market are increasing demand for safe blood transfusions and advanced diagnostic tests to prevent transfusion-related infections, rising prevalence of blood disorders and surgical procedures requiring blood transfusions, and advancements in blood testing technologies and growing regulatory standards for blood safety.

Lucintel forecasts that, within the type category, kits and reagent is expected to witness higher growth over the forecast period due to cost-effectiveness and ease of use of diagnostic kits and reagents in various healthcare settings.

Within the application category, blood bank is expected to witness the higher growth due to stringent regulatory requirements and high volume of blood collection and storage.

In terms of region, North America is expected to witness the highest growth over the forecast period due to stringent regulatory frameworks and significant investment in healthcare systems.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Donor Transfusion Diagnosis Market

Emerging trends are transforming this donor transfusion diagnosis market landscape at a lightning pace. Technological advances, regulatory changes, and market needs are driving these changes. Their focus is on improving diagnosis accuracy, reducing the risks of adverse transfusion complications, and optimizing blood donor management processes. Here are five key trends in the market today:.

• Integration of Artificial Intelligence in Blood Screening: Increased incorporation of AI-based solutions in donor screening tests is aimed at increasing the accuracy and efficiency of diagnosis. The AI algorithm continuously learns to analyze complex patterns of donor blood that help identify pathogens, achieve compatibility, and find the best matching blood for transfusion. Since results are quickly obtained and the chance of making a mistake due to human error is minimized, transfusions will be much safer. With advancements in AI, this technology may completely transform the whole process of diagnosis of donor transfusion, bringing about quicker, more reliable screening.
• Advancements in Nucleic Acid Testing: NAT has been developed as an essential tool to identify pathogens in the blood donated. The NAT methods enable detection of viral infections, such as HIV and hepatitis, with high sensitivity, thus making blood products safe for transfusion. In most regions, NAT is now becoming part of routine testing procedures and is helping in improving the quality of donated blood and reducing the risk of transfusion-transmitted infections. Expanding the usage of NATs is contributing considerably to the worldwide drive for safer blood transfusion practices.
• Transition to Automated Blood Screening Systems: Automation is changing how screening for blood takes place. Many high volume tests are currently done with great precision by utilizing the automated systems used for testing of blood, where many manual processes that are there will be bypassed. Automation facilitates easy completion, lowers the costs associated with human labor, and minimizes human error thus fast and highly accurate tests take place. Automated operations in the case of screening also enhance scalability: that is it is easy to increase volumes, allowing a number of donations at high safety levels.
• Focus on Pathogen Inactivation Technologies: Pathogen inactivation technologies are being increasingly used in the pursuit of safe blood transfusions. It is a method that aims to neutralize the presence of any pathogens within donated blood without compromising its quality. The emerging infectious diseases and multi-drug resistant organisms have increased the demand for advanced inactivation methods. With this extra layer of protection, pathogen inactivation technologies are becoming integral to the diagnosis and processing workflow of donor transfusion.
• Regulatory Changes and Higher Standards: The regulatory agencies across the world have been updating and strengthening the requirements for blood donation and transfusion diagnosis. More stringent screening processes and newer technologies for diagnostic processes are being integrated into the blood donation process. Regulatory changes have compelled the market to innovate and take on a higher level of safety, hence high-quality blood products. Changes in regulation also present opportunities for companies developing innovative diagnostic tools that help in the provision of safer donations of blood.

Emerging trends in the donor transfusion diagnosis market, such as AI integration, advancements in nucleic acid testing, automation, and pathogen inactivation technologies, are enhancing the efficiency, accuracy, and safety of blood screening. These innovations are significantly improving diagnostic processes, reducing risks associated with transfusions, and streamlining blood management. As these trends continue to evolve, they will reshape the market, contributing to higher standards of safety and operational efficiency in blood transfusion practices worldwide.

Recent Developments in the Donor Transfusion Diagnosis Market

Recent advances in the donor transfusion diagnosis market highlight the greater importance now placed on enhancing the safety of blood, diagnosis, and operational efficiency. Technologies and research inputs increasingly streamline the diagnostic process and improve pathogen detection capabilities while ensuring better quality blood products. Five advances currently drive the market are as follows:

• AI-Based Blood Screening: Artificial intelligence has become integral in advancing blood screening methods. AI algorithms now assist in identifying potential incompatibilities, abnormalities, and pathogens in blood donations. This helps to ensure higher accuracy and faster results compared to traditional manual methods. As AI continues to evolve, its potential for improving donor screening and transfusion safety grows, making it a cornerstone of future blood testing innovations.
• Advances in Nucleic Acid Testing (NAT): Nucleic acid testing (NAT) has improved dramatically, with new techniques that allow for the faster and more accurate detection of viral pathogens in blood donations. The increased use of NAT in routine screening has drastically reduced the risk of transfusion-transmitted infections, thereby improving the overall safety of blood transfusions worldwide. The continued refinement of NAT technology is poised to further enhance the detection capabilities of these diagnostic tools.
• Implementation of Automated Screening Systems: The increasing adoption of automated blood screening systems is changing the market by increasing throughput and minimizing human errors. These systems offer faster processing times, enabling large volumes of blood donations to be tested efficiently. The automation of testing processes helps reduce operational costs, minimize risks associated with manual handling, and improve the overall reliability of blood screening procedures.
• Next-Generation Sequencing (NGS) for Pathogen Detection: Advanced screening of blood would be achieved in third-generation sequencing in which NGS technologies are put into blood testing to provide ultrahigh-sensitivity and high selectivity pathogen detection. For instance, wide-ranging infections as rare and recently emerging pathogens were identified with significant accuracy than others. This could be a safety check for blood donated as the diseases that have not been known of before are fast increasing in menace.
• More Advanced Blood Kits: New diagnostic kits designed for screening blood have been made to make the testing more precise, faster, and cheaper. The kits can now be made available in the hospitals as well as remote locations; thus, there is an enhanced possibility of improvement in the safety of blood transfusions in underdeveloped countries.

Recent advancements in the donor transfusion diagnosis market, based on AI-powered screening, advanced pathogen detection, automation, and improved diagnostic kits, are improving blood safety and testing accuracy. These innovations are also reducing operational costs and testing time, driving the market towards more efficient and scalable solutions. As these technologies become more integrated into global blood transfusion systems, they will continue to improve the overall safety and management of blood donations.

Strategic Growth Opportunities in the Donor Transfusion Diagnosis Market

The donor transfusion diagnosis market offers many strategic growth opportunities for companies and healthcare service providers. The increasing demand for safe blood products, advancements in technology, and the necessity of more efficiency in transfusion practices have a wide range of applications where companies can capitalize on emerging trends. Five key growth opportunities across different applications in the market are given below:

• AI-Based Diagnostic Solutions Expansion: AI-driven solutions for donor screening and pathogen detection are expected to revolutionize the market. Companies that invest in these technologies can create even more precise, efficient, and scalable diagnostic platforms. AI can reduce test time substantially, improve the chances of compatibility matching, and enhance safety by identifying potential risks early. The widespread adoption of AI-based tools in the diagnosis of blood transfusion will open new business opportunities and improve patient outcomes.
• Expansion of Blood Management Programs: The demand for blood management systems is increasing as hospitals and blood banks look to optimize blood usage. These systems ensure that blood transfusion services are used efficiently, minimizing waste and ensuring that patients receive the right type of blood. The expansion of blood management programs, particularly in hospitals, presents significant opportunities for businesses providing diagnostic tools and software to improve blood screening, inventory, and donor management.
• Growing Demand for Pathogen Detection Technologies: The demand for advanced pathogen detection technologies, such as NAT and PCR, is increasing due to the growing concerns over emerging infectious diseases. Companies that are developing next-generation pathogen detection tools will have opportunities to address these safety concerns in blood donation systems. In addition, pathogen inactivation technologies are opening new avenues for growth by further enhancing transfusion safety.
• Adoption of Automation in Blood Screening: Automated blood screening technologies are an opportunity for growth. These systems minimize labor, improve accuracy, and increase throughput. As the need for blood donations is increasing around the world, fast, reliable, and scalable testing will be needed. Providers of automated screening technologies will be instrumental in meeting that need.
• Focus on Emerging Markets: Asia and Africa are major growing markets where donors transfusion diagnosis companies will enjoy significant growth potential. Their health infrastructure is rapidly expanding and there is significant investment in the improvement of blood safety. In entering these markets, companies will enjoy new streams of revenue, coupled with opportunities for contributing to international blood safety.

Major opportunities in the donor transfusion diagnosis market would include AI-based diagnostic solutions, expansion of blood management programs, advancements in pathogen detection, and automation, coupled with entry into emerging markets. These opportunities enable companies to further develop more efficient, affordable, and scalable solutions for improving the overall safety and practice of transfusion. Increased demand for better and more effective blood management systems will drive forward this strategic area.

Donor Transfusion Diagnosis Market Driver and Challenges

The donor transfusion diagnosis market is affected by many technological, economic, and regulatory factors. Some drivers are propelling this market forward, but regulatory hurdles, high costs, and infrastructure limitations remain some of the challenges. To help companies understand the challenges and drivers for navigating this market, below are the major drivers and challenges.

The factors responsible for driving the donor transfusion diagnosis market include:

1. Technological Advancements: Advances in diagnostic technologies include AI, nucleic acid testing, and automation. These will enhance the speed, accuracy, and efficiency with which blood is screened, thus resulting in safer transfusions. Also, they reduce operational costs, making it easier for the hospitals and the blood banks to manage blood donations more effectively.

2. Increasing Demand for Safe Blood: Increasing demand for safe blood products from population growth, aging populations, and more frequent medical procedures has become the major factor behind the increasing need for advanced donor transfusion diagnostic solutions. Such a demand would sustain the market's growth in the coming years, mainly in the regions of high healthcare demand.

3. Regulatory Pressure: Strengthening safety standards for blood donations and transfusions by governments and regulatory bodies will establish strong demand for more credible diagnostic tools. With stricter regulatory requirements, the companies need to innovate to meet these standards, leaving room for growth ahead.

4. Increased Transfusion Safety Awareness: Increased awareness of risk with transfusion is forcing service providers to undertake better diagnostic approaches in order to provide safe blood. This forces increased adoption levels of advanced screening technology.

5. Improved Health Infrastructure: The healthcare system, particularly in emerging markets, is experiencing expansion. Therefore, there is a growing demand for more effective blood diagnostic solutions. The increase in the number of hospitals and blood banks requires the establishment of more efficient and reliable blood screening and transfusion systems.

Challenges in the donor transfusion diagnosis market are:

1. High Cost of Advanced Technologies: One of the key challenges is the high cost of implementing advanced diagnostic technologies, which may limit their adoption in developing regions or smaller healthcare settings. The reduction of costs without compromising the efficacy of these technologies will be essential for broader application.

2. Regulatory Compliance: Companies operating internationally may have difficulties complying with the varying standards of different regulatory regions. Onerous and sophisticated regulations can significantly delay the release of new products as well as cost more to run, making access to the market difficult.

3. Infrastructure Limitations in Emerging Markets: In some emerging markets, limited infrastructure and lack of skilled personnel are barriers to the adoption of advanced diagnostic technologies. It will require considerable investment in training and infrastructure development to overcome these challenges.

The donor transfusion diagnosis market is driven by technological advancements, regulatory changes, and increasing demand for blood safety. However, challenges such as high costs and regulatory complexities continue to pose barriers. Companies that navigate these drivers and challenges effectively will find significant opportunities for growth, particularly through innovation and by expanding into emerging markets. As the market evolves, these factors will continue to reshape how blood transfusions are managed globally, ensuring safer and more efficient practices.

List of Donor Transfusion Diagnosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies donor transfusion diagnosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the donor transfusion diagnosis companies profiled in this report include-

• Grifols
• F. Hoffmann-La Roche
• Abbott
• Bio-Rad Laboratories
• Werfen
• Quidelortho Corporation
• Alivedx Holdings Finance
• Bag Diagnostics Gmbh
• Diasorin
• Prestige Diagnostics

Donor Transfusion Diagnosis Market by Segment

The study includes a forecast for the global donor transfusion diagnosis market by type, application, and region.

Donor Transfusion Diagnosis Market by Type [Value from 2019 to 2031]:

• Instruments
• Kits and Reagents

Donor Transfusion Diagnosis Market by Application [Value from 2019 to 2031]:

• Blood Banks
• Blood Donation
• Others

Donor Transfusion Diagnosis Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Donor Transfusion Diagnosis Market

Recent developments in the donor transfusion diagnosis market have been driven by advancements in technology, regulatory frameworks, and increasing demand for blood safety and compatibility testing. This market includes innovations aimed at improving diagnostic accuracy, reducing the risk of transfusion-related complications, and optimizing donor screening procedures. Key players in this sector are introducing cutting-edge solutions, including automation, artificial intelligence, and next-generation diagnostic tools. These are some of the advancements since blood transfusion practices are advancing to meet growing needs for safe and efficient blood management, especially for high transfusion-demanding countries such as the United States, China, Germany, India, and Japan.

• United States: In the United States, the donor transfusion diagnosis market has been highly developed, especially when automation and machine learning technologies were introduced. The FDA has been working to improve the standards of blood screening, which in turn has led to more reliable diagnostic tools. Companies are increasingly adopting high-throughput screening technologies that reduce testing times and costs. Advances in NAT also improve the detection of infectious agents in blood donations, providing a higher level of safety for recipients. In summary, the U.S. market is adopting technological advances to improve diagnostic procedures while also ensuring that donor-transfusion compatibility is established.
• China: China's donor transfusion diagnosis market is increasing rapidly because of the country's aging population and increased number of medical interventions. The government in China has increased blood safety standards, hence strict screening measures on blood donation are being conducted. Moreover, introduction of next generation diagnostic technologies that also encompass multiplex PCR testing is simultaneously detecting different kinds of pathogens in the body. China is now experiencing an upward trend in Blood management programs coupled with AI based optimization of blood donors' management in the country, and all of these factors result in a healthy and efficient Blood transfusion systems in the whole country.
• Germany: Germany is known for its highly developed healthcare system, and its donor transfusion diagnosis market is marked by a strong emphasis on regulatory compliance and technological advancement. The use of next-generation sequencing (NGS) and PCR-based testing methods has enhanced the accuracy and speed of donor screening, ensuring blood safety. Additionally, Germany is investing in research to develop more efficient diagnostic platforms that reduce time and cost. The market also benefits from strong collaborations between healthcare providers, government agencies, and diagnostic companies, which are continually refining processes to improve blood transfusion safety and management.
• India: India's donor transfusion diagnosis market is growing due to an expanding healthcare infrastructure and increasing awareness of blood safety. The government has introduced new policies to standardize blood donation screening processes, contributing to improved safety. Automated blood screening devices, and now affordable kits, are proving beneficial in increased test accuracy without increasing the error level. India also increasingly adopts a superior diagnostic test known as NAT in place of routine culturing or staining for increased sensitivity in detection of pathogens. Such changes are expected in India along with the expansion in the utilization of blood and its products for safe transfusion purposes.
• Japan: Donor Transfusion Diagnosis In Japan, in particular, Donor Transfusion Diagnosis is rising steadily and depends on the general healthcare infrastructure along with an interest of precision medicine prevailing in this region. This includes the integration of gene sequencing to improve donor screen accuracy. A country investing money in an upgrading process, mostly in relation to the entire overall efficiency of management systems and through automated testing machinery that helps them reduce the time and processing. Japan's rigorous regulatory environment ensures that diagnostic practices meet the highest standards, and innovations in pathogen detection are enhancing transfusion safety, especially in light of recent challenges posed by emerging infectious diseases.

Features of the Global Donor Transfusion Diagnosis Market

Market Size Estimates: Donor transfusion diagnosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Donor transfusion diagnosis market size by type, application, and region in terms of value ($B).

Regional Analysis: Donor transfusion diagnosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the donor transfusion diagnosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the donor transfusion diagnosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the donor transfusion diagnosis market by type (instruments and kits and reagents), application (blood banks, blood donation, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Donor Transfusion Diagnosis Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Donor Transfusion Diagnosis Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Donor Transfusion Diagnosis Market by Type
  • 3.3.1: Instruments
  • 3.3.2: Kits and Reagents
• 3.4: Global Donor Transfusion Diagnosis Market by Application
  • 3.4.1: Blood Banks
  • 3.4.2: Blood Donation
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Donor Transfusion Diagnosis Market by Region
• 4.2: North American Donor Transfusion Diagnosis Market
  • 4.2.1: North American Market by Type: Instruments and Kits and Reagents
  • 4.2.2: North American Market by Application: Blood Banks, Blood Donation, and Others
• 4.3: European Donor Transfusion Diagnosis Market
  • 4.3.1: European Market by Type: Instruments and Kits and Reagents
  • 4.3.2: European Market by Application: Blood Banks, Blood Donation, and Others
• 4.4: APAC Donor Transfusion Diagnosis Market
  • 4.4.1: APAC Market by Type: Instruments and Kits and Reagents
  • 4.4.2: APAC Market by Application: Blood Banks, Blood Donation, and Others
• 4.5: ROW Donor Transfusion Diagnosis Market
  • 4.5.1: ROW Market by Type: Instruments and Kits and Reagents
  • 4.5.2: ROW Market by Application: Blood Banks, Blood Donation, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Donor Transfusion Diagnosis Market by Type
  • 6.1.2: Growth Opportunities for the Global Donor Transfusion Diagnosis Market by Application
  • 6.1.3: Growth Opportunities for the Global Donor Transfusion Diagnosis Market by Region
• 6.2: Emerging Trends in the Global Donor Transfusion Diagnosis Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Donor Transfusion Diagnosis Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Donor Transfusion Diagnosis Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Grifols
• 7.2: F. Hoffmann-La Roche
• 7.3: Abbott
• 7.4: Bio-Rad Laboratories
• 7.5: Werfen
• 7.6: Quidelortho Corporation
• 7.7: Alivedx Holdings Finance
• 7.8: Bag Diagnostics Gmbh
• 7.9: Diasorin
• 7.10: Prestige Diagnostics